FDA's Unlikely Defenders
This article was originally published in RPM Report
Executive Summary
The primacy of FDA-approved labeling has an unlikely advocate. The Washington Legal Foundation is joining the EPO coverage dispute to tell CMS not to step into FDA’s turf.